This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant

This study has been withdrawn prior to enrollment.
(patients' reluctance)
Information provided by (Responsible Party):
Xiaojun Huang, Peking University People's Hospital Identifier:
First received: June 8, 2012
Last updated: September 27, 2016
Last verified: September 2016

The use of peripheral blood stem cells(PBSCs) is rapidly growing in the allogeneic transplantation setting as an alternative to bone marrow (BM).It was found that the use of PBSCs is associated with faster hematologic recovery but have yielded differing results regarding the incidence of graft-versus-host-disease (GVHD) and relapse.

The study hypothesis:

transplantation of mobilized PBSC to haploidentical donor with standard-risk leukemia had comparable engraftment and non-relapse mortality to mobilized BM combined with PBSCs

Condition Intervention
Leukemia Procedure: transplant with PBSCs

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia

Resource links provided by NLM:

Further study details as provided by Xiaojun Huang, Peking University People's Hospital:

Primary Outcome Measures:
  • incidence of engraftment [ Time Frame: paticipants will be followed for the duration of hospital stay,an expected average of 30 days ]
    number of participants with engraftment at 30d

Secondary Outcome Measures:
  • incidence of non-relapse mortality [ Time Frame: 1 year ]
    number of participants with non-relapse mortality at 1 year

Enrollment: 0
Study Start Date: October 2015
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: procedure/surgery
transplant with G-CSF mobilized PBSCs
Procedure: transplant with PBSCs
mobilized PBSCs for 2 consecutive days
Other Name: G-CSF mobilized peripheral blood stem cells
No Intervention: other
no intervention after transplant with mobilized BMPB

Detailed Description:
The donors were primed with granulocyte-colony stimulating factor (G-CSF) injected subcutaneously for five consecutive days. In the trial group, the PBSCs were harvested on the fourth and fifth day;in the control group, the bone marrow cells were harvested on the fourth day and the PBSCs were harvested on the fifth day.

Ages Eligible for Study:   2 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Standard risk of Recipients of haploidentical stem cell transplantation with myeloablative conditioning regimens

Exclusion Criteria:

  • Active, uncontrolled infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01617473

Peking University People'S Hospital
Beijing, China, 100044
Sponsors and Collaborators
Peking University People's Hospital
Principal Investigator: Xiao-Jun Huang, M.D. Peking University People's Hospital
  More Information

Responsible Party: Xiaojun Huang, chief of peking university institute of hematology, Peking University People's Hospital Identifier: NCT01617473     History of Changes
Other Study ID Numbers: PUPH IRB [2012] (27)
Study First Received: June 8, 2012
Last Updated: September 27, 2016

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms processed this record on August 18, 2017